| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.2 | 207.8 |
| Net income | -125.7 | 119.2 |
| EPS (diluted, $ a share) | $-1.22 | $1.33 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -95.1% |
|---|
10-Q filed with the SEC, NASDAQ: IDYA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ideaya Biosciences, Inc.: key numbers
- Share price
- $30.36Close, Nov 16
- Market cap
- $2.94B
- Shares outstanding
- 96.69MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ideaya Biosciences, Inc.
All →Ideaya Biosciences Financial Results
IDEAYA Biosciences reported Q3 2026 financial results, highlighting the completion of its first NDA submission for darovasertib in metastatic uveal melanoma. The company maintains a strong balance sheet with $1.15 billion in cash and equivalents, providing a projected cash runway into 2030.
- Term
- Q3 2026
“We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma. We also provided multiple clinical data updates at ESMO on darovasertib to support its potential as a foundational therapy across the entire uveal melanoma treatment journey as well as updated data from IDE849, our DLL3 TOP1 ADC, in relapsed SCLC and NEC.”
Yujiro S. Hata, Chief Executive Officer of IDEAYA
Ideaya Biosciences President and CEO Yujiro S. Hata Sells $985K of Stock
Yujiro S. Hata, President and CEO, sold 26,338 shares of Ideaya Biosciences, Inc. at $37.39 to $38.26 a share (average $37.41) in 2 transactions, worth $985K in total on Oct 6, 2026. Shares held after the trade: 690,695 (-0.1%).
- Value
- $985K
- Shares
- 26,338
- Average price
- $37.41
- Role
- President and CEO
- Holding change
- -0.1%
- Trade date
- Oct 6, 2026